Virinder Nohria, M.D., Ph.D., is an experienced biotechnology entrepreneur and drug developer with a track record of success in the pharmaceutical and biotechnology sector. In addition to his work with Marinus, Dr. Nohria serves as President of Vidara Therapeutics, a privately held biopharmaceutical company which he co-founded. In the past, Dr. Nohria was Chief Medical Officer, Chief Compliance Officer and Executive Vice President of Alaven Pharmaceutical and Alaven Consumer Health, LLC. Dr. Nohria worked for Eli Lilly on Zyprexa® (olanzapine) and at UCB, where he was clinical lead for submission and commercialization of Keppra® (levetiracetam) in the USA. Between 2003 and 2005, he was Vice President and Chief Medical Officer of Xcel Pharmaceuticals, where he led development of retigabine (ezogabine) for the treatment of epilepsy. Dr. Nohria is on the board of Promentis Pharmaceuticals, Inc., a privately held early stage neuroscience company. Dr. Nohria is a board-certified neurologist with special qualification in child neurology. His medical training was conducted at the University of Cambridge in England. His postgraduate training was completed at Duke University. He also holds a Ph.D. in neuropharmacology. He has authored many publications and book chapters.